Fund Holdings — Lynx1 Capital Management LP

Total Portfolio Value
$276.70M
Total Bought
$52.78M
Total Sold
$154.06M
Net Transaction
-$101.27M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q1 2024
▲▼
Q2 2024
▲▼
Change
▲▼
Q1 2024
▲▼
Q2 2024
▲▼
Weight (%)
▲▼
Change
▲▼
STOKE THERAPEUTICS INC(STOK)3,696,8205,185,191+1,488,37149,90770,05225.32%+20,145
GH RESEARCH PLC(GHRS)3,310,5633,966,726+656,16335,29146,25216.72%+10,961
CULLINAN THERAPEUTICS INC(CGEM)0377,323+377,32306,5812.38%+6,581
ALLOGENE THERAPEUTICS INC02,228,295+2,228,29505,1921.88%+5,192
LONGBOARD PHARMACEUTICALS IN0167,317+167,31704,5231.63%+4,523
MERUS N V1,509,0071,206,707-302,30067,95171,40125.80%+3,450
C4 THERAPEUTICS INC(CCCC)3,634,6626,880,527+3,245,86529,69531,78811.49%+2,093
PIERIS PHARMACEUTICALS INC043,499+43,49904270.15%+427
KINIKSA PHARMACEUTICALS INTL(KNSA)09,500+9,50001770.06%+177
KORRO BIO INC(KRRO)03,800+3,80001290.05%+129
VYNE THERAPEUTICS INC(YARW)016,194+16,1940320.01%+32
CENTESSA PHARMACEUTICALS PLC17,40017,40001971570.06%-39
BIONOMICS LIMITED814,467599,673-214,7948394600.17%-379
IBIO INC(IBIO)600,000600,00002,4361,2660.46%-1,170
PIERIS PHARMACEUTICALS INC8,779,1620-8,779,1621,6080—-1,608
NEKTAR THERAPEUTICS(NKTR)2,068,8420-2,068,8421,9330—-1,933
PASSAGE BIO INC(PASG)4,845,8715,057,629+211,7586,5424,0171.45%-2,525
KINNATE BIOPHARMA INC1,981,1060-1,981,1065,2700—-5,270
AUTOLUS THERAPEUTICS PLC(AUTL)1,390,1600-1,390,1608,8690—-8,869
TSCAN THERAPEUTICS INC(TCRX)5,224,6005,224,600041,48330,56411.05%-10,919
SILENCE THERAPEUTICS PLC(SLN)526,6420-526,64211,3750—-11,375
CABALETTA BIO INC(CABA)2,082,973492,103-1,590,87035,5363,6811.33%-31,855
ALPINE IMMUNE SCIENCES INC2,253,1830-2,253,18389,3160—-89,316
Page 1 of 1
Lynx1 Capital Management LP — 13F Holdings — Q2 2024 | TickerTrail